^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

vididencel (DCP-001)

i
Other names: DCP-001, DCP001, DCOne
Company:
Mendus
Drug class:
Immunostimulant
Related drugs:
5ms
Enrollment closed
|
CTAG1B (Cancer/testis antigen 1B)
|
vididencel (DCP-001)
5ms
New P2 trial
|
NPM1 (Nucleophosmin 1)
|
Onureg (azacitidine oral) • vididencel (DCP-001)
1year
Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine (ASH 2023)
The locally skin induced immune response leading to influx of a plethora of immune cells, confirmed the mode of action of immune priming through intradermal administration of the cancer vaccine. These results warrant further studies combining vididencel with SOC such as hypomethylating agents in AML maintenance.
Clinical • IO biomarker
|
TP53 (Tumor protein P53) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • CD8 (cluster of differentiation 8) • RUNX1 (RUNX Family Transcription Factor 1) • IFNG (Interferon, gamma) • WT1 (WT1 Transcription Factor) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • CD4 (CD4 Molecule) • PRAME (Preferentially Expressed Antigen In Melanoma) • CDK1 (Cyclin-dependent kinase 1)
|
TP53 mutation • NPM1 mutation
|
vididencel (DCP-001)
1year
Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients (ASH 2023)
Patients who remain in CR after vididencel treatment had highest baseline levels of HLA-DR+ CD45RA+ cells, which could be myeloid cells able to differentiate into dendritic cell subsets, as in general CD45RA+ is lost during maturation from precursor to matured dendritic cells. Vaccination might improve and induce maturation of dendritic cell subsets, such as cDC1, cDC2 and pDC, which enhance antigen capturing, processing and presentation to tumor-reactive T cells, ultimately leading to improved survival.
Clinical • IO biomarker
|
CD8 (cluster of differentiation 8) • CD123 (Interleukin 3 Receptor Subunit Alpha) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CDK1 (Cyclin-dependent kinase 1) • CD1C (CD1c Molecule)
|
CD123 expression
|
vididencel (DCP-001)
1year
Intradermal Vaccination with Vididencel in MRD+ AML-Patients Leads to Increase in Antigen Presenting Cells and T-Cells to the Injection Site, Visualized Using Imaging Mass Cytometry, Showing Local Immune Cell Interactions Leading to Systemic Immune Responses (ASH 2023)
The observed co-localization of the different immune subsets following vaccination supports the hypothesis of local antigen capturing by blood derived and local antigen presenting cells (Zuo et al, 2021). The local immune response may ultimately leads to a systemic immune response and disease control.
Clinical • IO biomarker • Immune cell
|
CD8 (cluster of differentiation 8) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD1C (CD1c Molecule)
|
CD38 positive • CD4 positive
|
vididencel (DCP-001)
over1year
TREATMENT WITH A LEUKEMIA-DERIVED DENDRITIC CELL VACCINE INDUCES INNATE AND ADAPTIVE IMMUNE RESPONSE CORRELATING WITH CLINICAL RESPONSE IN AML PATIENTS IN CR1 WITH MEASURABLE RESIDUAL DISEASE (EHA 2023)
In conclusion, immunotherapy with vididencel is able to induce immune responses in AML patients in CR1 after chemotherapy induction/consolidation, with the number of responses correlating positively with clinicalresponses. Additionally, the vaccine induces a broader immune activation, in both the innate and adaptive immune system, and reduces the number of inhibiting CD8Lag3+ T-cells. This leads to reduction of residual disease in a proportion of patients and promising relapse-free and overall survival.
Clinical • IO biomarker
|
CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • WT1 (WT1 Transcription Factor) • CD4 (CD4 Molecule) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
vididencel (DCP-001)
over1year
Evaluation of immune response to tumor associated antigens in patients with high grade serous ovarian cancer vaccinated intra-dermally with DCP-001, an allogeneic, cancer cell-based vaccine (AACR 2023)
Taken together, initial data from the phase I trial demonstrate that DCP-001 is safe and well-tolerated and induces durable T-cell responses to tumor associated antigens in OC patients. The study will continue to enroll new patients, follow-up for progression and overall survival and will further analyze the immune responses induced by DCP-001.
Clinical
|
IFNG (Interferon, gamma) • WT1 (WT1 Transcription Factor) • CTAG1B (Cancer/testis antigen 1B) • PRAME (Preferentially Expressed Antigen In Melanoma) • MAGEA3 (MAGE Family Member A3)
|
vididencel (DCP-001)
2years
Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens (ASH 2022)
Relapse on study was limited, with an estimated RFS at 6 months of 83.7%, which is higher than expected for this MRD+ AML patient population, which would be around 45% as shown for placebo-treated patients from a recent phase III study in a similar patient population (Quazar AML001). Immunotherapy with DCP-001 as AML maintenance therapy is safe and effective in triggering immune responses and converting patients from MRD positive to MRD negative, leading to promising relapse-free survival.
Clinical • IO biomarker
|
TP53 (Tumor protein P53) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • CD8 (cluster of differentiation 8) • RUNX1 (RUNX Family Transcription Factor 1) • IFNG (Interferon, gamma) • WT1 (WT1 Transcription Factor) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
TP53 mutation • NPM1 mutation
|
vididencel (DCP-001)
2years
Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion (ASH 2022)
In this phase II study (ADVANCE-II, Clintrials.gov: NCT03697707) AML patients in first complete remission (CR1), with measurable residual disease (MRD), ineligible for HSCT, were treated with an intradermal allogenic leukemia-derived dendritic cell vaccine (DCP-001)...Higher numbers of circulating autologous DC in combination with CD8 effector T-cells, instead of high CD8 CM T-cells might be a prerequisite for successful vaccination to prevent relapse or MRD conversion. Improvement in DC frequencies were observed in patients with stable MRD, which might suggest the potential for more booster vaccinations using this vaccine.
Clinical
|
CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor) • CD68 (CD68 Molecule) • PRAME (Preferentially Expressed Antigen In Melanoma) • CDK1 (Cyclin-dependent kinase 1)
|
CD8-H • CD68 positive
|
vididencel (DCP-001)
2years
ADVANCE-II: Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia (clinicaltrials.gov)
P2, N=20, Active, not recruiting, Mendus | Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Mar 2022 --> Mar 2023
Trial completion date • Trial primary completion date
|
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
|
vididencel (DCP-001)
over2years
The cancer relapse vaccine DCP-001 acts synergistically with 5’-azacitidine/venetoclax treatment in a preclinical AML model (CIMT 2022)
The data of mean tumor volume (± SEM) 6 weeks after therapy initiation was significantly reduced in the combination group (181.8 ± 29 mm3) as compared to control (522 ± 97.5 mm3), but also vaccination (326.9 ± 54.6 mm3) or drug treatment alone (293.8 ± 29 mm3). Taken together, these preclinical results support the use of DCP-001 as a potential combination therapy with 5-AZA-VEN in AML and related hematological malignancies.
Preclinical
|
CD34 (CD34 molecule)
|
Venclexta (venetoclax) • azacitidine • vididencel (DCP-001)
almost3years
Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade. (PubMed, Cells)
These data suggest that, following intradermal DCP-001 vaccination, local and recruited host APCs capture tumor-associated antigens from the vaccine, become activated and migrate to the draining lymph nodes to subsequently (re)activate tumor-reactive T-cells. The improved uptake of DCP-001 by blocking CD47 rationalizes the possible combination of DCP-001 vaccination with CD47 blocking therapies.
Journal
|
CALR (Calreticulin)
|
vididencel (DCP-001)
almost3years
ALISON: Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment (clinicaltrials.gov)
P1, N=17, Recruiting, University Medical Center Groningen | Not yet recruiting --> Recruiting | Trial completion date: Mar 2026 --> Jun 2026 | Initiation date: Mar 2021 --> Jun 2021 | Trial primary completion date: Mar 2025 --> Jun 2025
Clinical • Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
|
BIRC5 (Baculoviral IAP repeat containing 5) • CTAG1B (Cancer/testis antigen 1B) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
vididencel (DCP-001)
3years
Clinical • Enrollment closed
|
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
|
vididencel (DCP-001)
over3years
[VIRTUAL] ENHANCED EFFICACY OF THE DCP-001 RELAPSE VACCINE WHEN COMBINED WITH VENETOCLAX AND 5-AZACITIDINE IN A HUMANISED IMMUNOCOMPETENT MOUSE MODEL OF AML (EHA 2021)
Off target effects of drug treatment reduced circulating human immune cells, suggesting optimization of treatment and vaccination scheduling may further enhance the anti-leukemic effect of the combination therapy. These preclinical results support use of DCP-001 as add-on to treatment with AZA-VEN in clinical trials in AML patients.
Preclinical
|
CD19 (CD19 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
PTPRC expression
|
Venclexta (venetoclax) • azacitidine • vididencel (DCP-001)
over3years
[VIRTUAL] INDUCED SYSTEMIC T-CELL SPECIFIC RESPONSES TO MULTIPLE TUMOR-ASSOCIATED ANTIGENS AFTER ALLOGENIC LEUKEMIA-DERIVED DENDRITIC CELL VACCINE DCP-001 IN AML PATIENTS WITH PERSISTENT MRD (EHA 2021)
In both patients multiple antigenic responses after DCP-001 vaccination and high levels of immune cells infiltrates at the injection site were observed. Conclusion DCP-001 used as a relapse vaccine in AML patients, showed recruitment of immune cells to the skin, increased cellular responses to a broad range of tumor associated antigens, and resulted in reversion of the MRD status in some patients.
Clinical
|
CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor) • CTAG1B (Cancer/testis antigen 1B) • CD4 (CD4 Molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9) • CD68 (CD68 Molecule) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
vididencel (DCP-001)
almost4years
Clinical • New P1 trial
|
BIRC5 (Baculoviral IAP repeat containing 5) • CTAG1B (Cancer/testis antigen 1B) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
vididencel (DCP-001)
almost4years
ADVANCE-II: Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia (clinicaltrials.gov)
P2, N=20, Recruiting, DCPrime BV | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Mar 2022
Clinical • Trial completion date • Trial primary completion date
|
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
|
vididencel (DCP-001)
4years
[VIRTUAL] Conversion from MRD Positive to Negative Status in AML Patients in CR1 after Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine (ASH 2020)
The allogeneic leukemia-derived dendritic cell vaccine, DCP-001, has shown in a phase I study to generate both humoral and cellular immune responses and is safe for clinical practice (van de Loosdrecht et al., Cancer Immunol...These patients continue to be in complete remission for at least a year after vaccination. This study continues to enroll patients at a higher vaccine dose of 50.106cells per vaccination and additional data on induced immune responses and MRD status will be shown.
Clinical
|
NPM1 (Nucleophosmin 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
vididencel (DCP-001)